Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — April 2014

Planlagt Fastgjort Låst Flyttet Genmab
2.4k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • celsiusC Offline
    celsiusC Offline
    celsius
    wrote on sidst redigeret af
    #1486

    Så kommer afgørelsen inden for en time gætter jeg på

    1 Reply Last reply
    0
    • J Offline
      J Offline
      JKY_VH
      wrote on sidst redigeret af
      #1487

      Mon ikke det først er i morgen?

      1 Reply Last reply
      0
      • JørgenVarnæsJ Offline
        JørgenVarnæsJ Offline
        JørgenVarnæs
        wrote on sidst redigeret af
        #1488

        det er også mit bud, men vi er helt oppe imod målstregen lige nu - så den kan vel falde nårsomhelst!!!

        1 Reply Last reply
        0
        • J Offline
          J Offline
          JSEH
          wrote on sidst redigeret af
          #1489

          Genmab A/S (GMXAY) -Other OTC
          17.67 Up 0.65(3.82%) 12:24PM EDT

          1 Reply Last reply
          0
          • J Offline
            J Offline
            JSEH
            wrote on sidst redigeret af
            #1490

            Volume: 1,177

            1 Reply Last reply
            0
            • G Offline
              G Offline
              gentogen
              wrote on sidst redigeret af
              #1491

              Comparison of CDC activity using rituximab and ofatumumab revealed that the cytotoxic activity of ofatumumab was significantly higher than that of rituximab. http://onlinelibrary.wiley.com/doi/10.1111/bjh.12857/full

              1 Reply Last reply
              0
              • G Offline
                G Offline
                gentogen
                wrote on sidst redigeret af
                #1492

                she was receiving ofatumumab, a humanized anti-CD20 monoclonal antibody approved by the Food and Drug Administration for the treatment of multidrug-resistant CLL, with efficacy against rituximab-resistant B-cell cancers.4 Therapy with ofatumumab produced a dramatic response in the patient's renal status

                1 Reply Last reply
                0
                • G Offline
                  G Offline
                  gentogen
                  wrote on sidst redigeret af
                  #1493

                  Just a moment...

                  favicon

                  (www.nejm.org)

                  1 Reply Last reply
                  0
                  • G Offline
                    G Offline
                    gentogen
                    wrote on sidst redigeret af
                    #1494

                    Recent studies show that ofatumumab can replace rituximab in the fludarabine/cyclophosphamide/rituximab regimen for patients with CLL.

                    1 Reply Last reply
                    0
                    • G Offline
                      G Offline
                      gentogen
                      wrote on sidst redigeret af
                      #1495

                      301 Moved Permanently

                      favicon

                      (www.theoncologynurse.com)

                      1 Reply Last reply
                      0
                      • G Offline
                        G Offline
                        gentogen
                        wrote on sidst redigeret af
                        #1496

                        A phase 2 trial confirmed comparable high activity and safety of the O-FC (ofatumumab/fludarabine/cyclophosphamide) regimen as frontline treatment of previously untreated CLL. Investigators are moving forward with this regimen using the 1000-mg dose of ofatumumab.

                        1 Reply Last reply
                        0
                        • G Offline
                          G Offline
                          gentogen
                          wrote on sidst redigeret af
                          #1497

                          a combination of ofatumumab plus lenalidomide has been tested extensively at MD Anderson Cancer Center and shown to be extremely effective. Studies show an overall response rate of 68 percent and a complete response rate of 24 percent.

                          1 Reply Last reply
                          0
                          • BudweisB Offline
                            BudweisB Offline
                            Budweis
                            wrote on sidst redigeret af
                            #1498

                            Det ser ikke så tosset ud

                            1 Reply Last reply
                            0
                            • G Offline
                              G Offline
                              gentogen
                              wrote on sidst redigeret af
                              #1499

                              Just a moment...

                              favicon

                              (journals.lww.com)

                              1 Reply Last reply
                              0
                              • G Offline
                                G Offline
                                gentogen
                                wrote on sidst redigeret af
                                #1500

                                favicon

                                (abstracts.hematologylibrary.org)

                                1 Reply Last reply
                                0
                                • G Offline
                                  G Offline
                                  gentogen
                                  wrote on sidst redigeret af
                                  #1501

                                  24% CR i relapsed CLL i 2012. Utroligt, at GSK er SÅ passive

                                  1 Reply Last reply
                                  0
                                  • JørgenVarnæsJ Offline
                                    JørgenVarnæsJ Offline
                                    JørgenVarnæs
                                    wrote on sidst redigeret af
                                    #1502

                                    rigtig flot luk i US med index oppe 2,5% - men mon ikke der er andet, der sætter dagsordenen på tirsdag....

                                    1 Reply Last reply
                                    0
                                    • J Offline
                                      J Offline
                                      JKY_VH
                                      wrote on sidst redigeret af
                                      #1503

                                      Betyder det, at appelsinerne atter forlader FF´s turban?

                                      1 Reply Last reply
                                      0
                                      • JørgenVarnæsJ Offline
                                        JørgenVarnæsJ Offline
                                        JørgenVarnæs
                                        wrote on sidst redigeret af
                                        #1504

                                        det er vist kun i hans eget hoved, at der har været appelsiner i hans turban

                                        1 Reply Last reply
                                        0
                                        • J Offline
                                          J Offline
                                          JKY_VH
                                          wrote on sidst redigeret af
                                          #1505

                                          jo,jo, men det var en kommentar fra dagens indslag i TV2-News om Genmabs nedtur som FF fik æren af, at have forudset....

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger